Sun Pharmaceutical Industries Ltd Share Price – NSE  / BSE

Pharmaceuticals, Mid Cap

Innovcare Lifesciences is engaged in the business of marketing, distribution and sale of pharmaceutical drugs, nutraceutical and cosmeceutical products. The revenue from operations for FY 2025-26 was Rs 94.06 crore.

Sun Pharma stated that this acquisition is being done to strengthen product portfolio of the company.

The company expects to complete this transaction before 31 July 2026.

Sun Pharmaceutical Industries is engaged in the business of manufacturing, developing and marketing a wide range of branded and generic formulations and active pharmaceutical ingredients (APIs). The company and its subsidiaries has various manufacturing facilities spread across the world, with trading and other incidental and related activities extending to global market. It is the largest pharmaceutical company in India.

The company had reported 26.24% rise in consolidated net profit to Rs 2,714.03 crore in Q4 FY26 as against Rs 2,149.88 crore posted in the same period year ago. Total revenue from operations increased 12.75% YoY to Rs 14,611.79 crore in the quarter ended 31 March 2026.

The scrip advanced 0.85% to currently trade at Rs 1852.70 on the BSE.

Powered by Capital Market - Live News

Securities in F&O Ban:

Shares of Kaynes Technology India are banned from F&O trading on 22 June 2026.

Stocks to Watch:

Sun Pharmaceuticals Industries has entered into an agreement to acquire 100% stake in Innovcare Lifesciences, based in Mumbai and engaged in the business of marketing, distribution and sale of pharmaceutical drugs, nutraceutical and cosmeceutical products. The total consideration of the transaction is valued at Rs 271.2 crore.

Garden Reach Shipbuilders & Engineers (GRSE) has been granted Navratna status by the Department of Public Enterprises (DPE) under the Ministry of Finance. The company said the recognition reflects its strong financial performance, operational efficiency and contribution to national security.

GE Power India announced a series of senior leadership changes, including the appointment of Rahul Rojal as Chief Financial Officer (CFO), as the company strengthens its management team amid ongoing business and project execution initiatives.

Goodluck India announced that its subsidiary, Goodluck Defence and Aerospace, has secured an order worth approximately Rs 255 crore for the supply of 155 mm long-range empty shells in ready-to-fill condition.

Zaggle Prepaid Ocean Services (Zaggle) announced that it has entered into an agreement with Punjab National Bank (PNB) to act as a co-branding partner for a retail credit card product. Under the agreement, Zaggle will leverage its existing corporate customer base to drive acquisition, marketing and promotion of the co-branded retail credit card. The partnership is aimed at expanding the reach of the co-branded card offering.

Texmaco Rail & Engineering has received a letter of intent (LoI) worth Rs 253.28 crore from JSW (South) Rail Logistics for the manufacture and supply of BFNSM1 rakes along with BVCM wagons. The domestic order is scheduled to be executed within 13.5 months from the effective date or commencement of work.

Powered by Capital Market - Live News

Sun Pharmaceutical Industries Ltd fell for a fifth straight session today. The stock is quoting at Rs 1774.1, down 0.81% on the day as on 13:19 IST on the NSE. The benchmark NIFTY is down around 0.22% on the day, quoting at 23353.3. The Sensex is at 74101.32, down 0.33%.Sun Pharmaceutical Industries Ltd has eased around 2.56% in last one month.Meanwhile, Nifty Pharma index of which Sun Pharmaceutical Industries Ltd is a constituent, has increased around 2.59% in last one month and is currently quoting at 24086.6, up 0.38% on the day. The volume in the stock stood at 11.66 lakh shares today, compared to the daily average of 29.77 lakh shares in last one month.

The benchmark June futures contract for the stock is quoting at Rs 1793.9, down 0.5% on the day. Sun Pharmaceutical Industries Ltd jumped 5.41% in last one year as compared to a 5.65% slide in NIFTY and a 11.71% spurt in the Nifty Pharma index.

The PE of the stock is 143.04 based on TTM earnings ending March 26.

Powered by Capital Market - Live News

Sun Pharmaceuticals Industries announced that the Board of Directors of the Company at its meeting held on 22 May 2026, inter alia, have recommended the final dividend of Rs 5 per equity Share (i.e. 500%) , subject to the approval of the shareholders.